These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 12846981)

  • 21. Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism.
    Hauser DN; Hastings TG
    Neurobiol Dis; 2013 Mar; 51():35-42. PubMed ID: 23064436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular changes in the postmortem parkinsonian brain.
    Toulorge D; Schapira AH; Hajj R
    J Neurochem; 2016 Oct; 139 Suppl 1():27-58. PubMed ID: 27381749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mitochondrial dysfunction in Parkinson's disease.
    Winklhofer KF; Haass C
    Biochim Biophys Acta; 2010 Jan; 1802(1):29-44. PubMed ID: 19733240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum levels of coenzyme Q10 in patients with Parkinson's disease.
    Jiménez-Jiménez FJ; Molina JA; de Bustos F; García-Redondo A; Gómez-Escalonilla C; Martínez-Salio A; Berbel A; Camacho A; Zurdo M; Barcenilla B; Enríquez de Salamanca R; Arenas J
    J Neural Transm (Vienna); 2000; 107(2):177-81. PubMed ID: 10847558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The coenzyme Q10 status of the brain regions of Parkinson's disease patients.
    Hargreaves IP; Lane A; Sleiman PM
    Neurosci Lett; 2008 Dec; 447(1):17-9. PubMed ID: 18840506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synergistic anti-Parkinsonism activity of high doses of B vitamins in a chronic cellular model.
    Jia H; Liu Z; Li X; Feng Z; Hao J; Li X; Shen W; Zhang H; Liu J
    Neurobiol Aging; 2010 Apr; 31(4):636-46. PubMed ID: 18639366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brain mitochondrial dysfunction and oxidative damage in Parkinson's disease.
    Navarro A; Boveris A
    J Bioenerg Biomembr; 2009 Dec; 41(6):517-21. PubMed ID: 19915964
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease.
    Zuo L; Motherwell MS
    Gene; 2013 Dec; 532(1):18-23. PubMed ID: 23954870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.
    Büeler H
    Exp Neurol; 2009 Aug; 218(2):235-46. PubMed ID: 19303005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuroprotective effects of coenzyme Q10 on paraquat-induced Parkinson's disease in experimental animals.
    Attia HN; Maklad YA
    Behav Pharmacol; 2018 Feb; 29(1):79-86. PubMed ID: 28902670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Damage to dopaminergic neurons by oxidative stress in Parkinson's disease (Review).
    Guo JD; Zhao X; Li Y; Li GR; Liu XL
    Int J Mol Med; 2018 Apr; 41(4):1817-1825. PubMed ID: 29393357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of coenzyme Q10 on the mitochondrial function of skin fibroblasts from Parkinson patients.
    Winkler-Stuck K; Wiedemann FR; Wallesch CW; Kunz WS
    J Neurol Sci; 2004 May; 220(1-2):41-8. PubMed ID: 15140604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune processes in the pathogenesis of Parkinson's disease - a potential role for microglia and nitric oxide.
    Członkowska A; Kurkowska-Jastrzebska I; Członkowski A; Peter D; Stefano GB
    Med Sci Monit; 2002 Aug; 8(8):RA165-77. PubMed ID: 12165754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Environmental toxins and Parkinson's disease: putative roles of impaired electron transport chain and oxidative stress.
    Abdulwahid Arif I; Ahmad Khan H
    Toxicol Ind Health; 2010 Mar; 26(2):121-8. PubMed ID: 20207656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SUMO-regulated mitochondrial function in Parkinson's disease.
    Guerra de Souza AC; Prediger RD; Cimarosti H
    J Neurochem; 2016 Jun; 137(5):673-86. PubMed ID: 26932327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polyhydroxylated fullerene derivative C(60)(OH)(24) prevents mitochondrial dysfunction and oxidative damage in an MPP(+) -induced cellular model of Parkinson's disease.
    Cai X; Jia H; Liu Z; Hou B; Luo C; Feng Z; Li W; Liu J
    J Neurosci Res; 2008 Dec; 86(16):3622-34. PubMed ID: 18709653
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nitrosylation and nitration of mitochondrial complex I in Parkinson's disease.
    Chinta SJ; Andersen JK
    Free Radic Res; 2011 Jan; 45(1):53-8. PubMed ID: 20815786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mitochondrial dysfunction in Parkinson's disease.
    Fukae J; Mizuno Y; Hattori N
    Mitochondrion; 2007; 7(1-2):58-62. PubMed ID: 17300997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New insights into the complex role of mitochondria in Parkinson's disease.
    Grünewald A; Kumar KR; Sue CM
    Prog Neurobiol; 2019 Jun; 177():73-93. PubMed ID: 30219247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson's disease.
    Sohmiya M; Tanaka M; Tak NW; Yanagisawa M; Tanino Y; Suzuki Y; Okamoto K; Yamamoto Y
    J Neurol Sci; 2004 Aug; 223(2):161-6. PubMed ID: 15337618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.